Helen Dolk

Risk of Congenital Ocular Anomaly After Prenatal Exposure to Medications: A <scp>EUROmediCAT</scp> Study

Antiretroviral drug exposure in pregnancy and risk of congenital anomalies: a European case/non-case malformed study

The EUROmediCAT network and databases: a resource for pharmacovigilance in pregnancy Short running title: The EUROmediCAT network and databases

Report on algorithms to define pregnancy, maternal morbidity and maternal, perinatal and childhood outcomes (D1.4)

Report on algorithms to define pregnancy, maternal morbidity and maternal, perinatal and childhood outcomes (D1.4)

Prevalence of Congenital Ocular Anomalies in 15 Countries of Europe: Results From the Medikeye Study

Submitted manuscript of a guidance document outlining lessons learned for conducting drug utilization and medication safety studies based on secondary data sources in pregnancy using the ConcePTION pipeline (D1.7)

Submitted manuscript of a guidance document outlining lessons learned for conducting drug utilization and medication safety studies based on secondary data sources in pregnancy using the ConcePTION pipeline (D1.7)

Risk of Congenital Ocular Anomaly in EUROmediCAT: Assessment of the Potential Risk of Taking Medications during Pregnancy in Europe

Polypharmacy during pregnancy and associated risk factors: a retrospective analysis of 577 medication exposures among 1.5 million pregnancies in the UK, 2000-2019

A population-based matched cohort study of major congenital anomalies following COVID-19 vaccination and SARS-CoV-2 infection

Expert consensus on neurodevelopmental outcomes in pregnancy pharmacovigilance studies

The burden, prevention and care of infants and children with congenital anomalies in sub-Saharan Africa: A scoping review

Detection and evaluation of signals associated with exposure to individual and combination of medications in pregnancy: a signal detection study protocol

Additional file 7 of Polypharmacy during pregnancy and associated risk factors: a retrospective analysis of 577 medication exposures among 1.5 million pregnancies in the UK, 2000-2019

Additional file 5 of Polypharmacy during pregnancy and associated risk factors: a retrospective analysis of 577 medication exposures among 1.5 million pregnancies in the UK, 2000-2019

Additional file 4 of Polypharmacy during pregnancy and associated risk factors: a retrospective analysis of 577 medication exposures among 1.5 million pregnancies in the UK, 2000-2019

Additional file 6 of Polypharmacy during pregnancy and associated risk factors: a retrospective analysis of 577 medication exposures among 1.5 million pregnancies in the UK, 2000-2019

Breastfeeding, pregnancy, medicines, neurodevelopment, and population databases: the information desert

Macrolide and lincosamide antibiotic exposure in the first trimester of pregnancy and risk of congenital anomaly: A European case-control study

Global birth defects app: An innovative tool for describing and coding congenital anomalies at birth in low resource settings

Signal Detection in EUROmediCAT: Identification and Evaluation of Medication–Congenital Anomaly Associations and Use of VigiBase as a Complementary Source of Reference

The legacy of ZikaPLAN: a transnational research consortium addressing Zika

Macrolide antibiotic exposure in the first trimester of pregnancy and risk of congenital anomaly: A European case-control study

Congenital clubfoot in Europe: A population‐based study

ZikaPLAN: addressing the knowledge gaps and working towards a research preparedness network in the Americas

Trends in congenital anomalies in Europe from 1980 to 2012

Metformin exposure in first trimester of pregnancy and risk of all or specific congenital anomalies: exploratory case-control study

Insulin analogues use in pregnancy among women with pregestational diabetes mellitus and risk of congenital anomaly: a retrospective population-based cohort study

Metformin Exposure in the First Trimester of Pregnancy and Risk of All or Specific Congenital Anomalies: Exploratory Case-Control Study